David Germonpre - Chief Financial Officer @ Adrenomed

Start Free Trial

Pricing

Overview

Number of Current Board & Advisor Roles

CB Rank (Investor)

167,891

Primary Job Title Chief Financial Officer
Primary Organization
Adrenomed

Location Switzerland, Europe
Regions Europe, Middle East, and Africa (EMEA)
Gender Male

Investor Type
obfuscated
obfuscation

LinkedIn View on LinkedIn

David Germonpré is the current Chief Financial Officer of Adrenomed. He previously worked at MTIP as a Partner. David Germonpré attended IE Business School.

Partner Investments

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	TrialBee	MTIP AG	—	Venture Round - TrialBee	obfuscated obfuscation
obfuscated obfuscation	Koa Health	MTIP AG	—	Series A - Koa Health	obfuscated obfuscation
obfuscated obfuscation	TrialBee	MTIP AG	Yes	Venture Round - TrialBee	obfuscated obfuscation

Jobs

Number of Current Jobs

Number of Past Jobs

David Germonpre

is the

Chief Financial Officer

Adrenomed

. Additionally,

David Germonpre

has had

past job as the

Partner

MTIP AG

Adrenomed Chief Financial OfficerJul 2022

Organization Name	Title At Company	Start Date	End Date
MTIP AG	Partner	Jan 2019	Mar 2022

Board and Advisor Roles

Number of Current Board & Advisor Roles

Number of Past Board & Advisor Roles

David Germonpre

is the

Board Member

TrialBee

TrialBee Board MemberApr 2020

Organization Name	Title At Company	Start Date	End Date
Koa Health	Board of Director	Dec 2020	Dec 2021

Related Hubs

Hub Name	CB Rank (Hub)
Medical Companies with Late Stage Venture Funding	31,127
Europe Late Stage Companies With Less Than $1B in Revenue	31,506
Biotechnology Late Stage Companies With More Than $1M in Revenue	45,271
Pharmaceutical Startups	18,263
Europe, Middle East, and Africa (EMEA) Startups Founded in 2009	63,128
Europe, Middle East, and Africa (EMEA) Late Stage Companies With Less Than $500M in Revenue	22,426
Biotechnology Late Stage Companies With Less Than $10M in Revenue	99,138
HBM Healthcare Investments Portfolio Companies	38,587
Wellington Partners Portfolio Companies	76,213
Europe, Middle East, and Africa (EMEA) Late Stage Companies With More Than $1M in Revenue	19,657